Brand versus compounded, on price: the spread is not what you were told
Compounded is usually cheaper, and that's most of why the compounded market exists. It isn't reliably cheaper. Reading 869 compounded and 91 brand GLP-1 prices off sellers' own pages, 22 brand lines sit at or below the middle of the compounded range — and the dearest compounded line across the sellers we review costs more than most of the brand ones.
What this comes down to
- Compounded GLP-1 prices here run $49 to $3497 a month with a middle of $199. Brand runs $99 to $1899 with a middle of $399.
- 22 of the 91 brand lines we have read sit at or below the middle of the compounded range. The two markets overlap.
- The brand range is bimodal: manufacturer direct-pay pricing sits at one end and retail brand pricing through a telehealth platform sits at the other, and they are not the same product experience.
- Whatever the spread, the compounded product was never reviewed by the FDA for safety, effectiveness or quality before sale, and the approved-product trials cited here do not establish equivalence for a compounded version.
- Compounded$199
- Brand$399
The two ranges, side by side
| Compounded | Brand | |
|---|---|---|
| Prices read | 869 | 91 |
| Sellers | 280 | 34 |
| Lowest | $49 | $99 |
| Lower quartile | $149 | $215.98 |
| Middle | $199 | $399 |
| Upper quartile | $279 | $1299 |
| Highest | $3497 | $1899 |
Every GLP-1 medication price across the sellers we review, split by form. Each figure was read off the seller's own page.
Read the quartiles rather than the extremes and the shape is clear. The compounded market is tight: half of it lives between $149 and $279. The brand market is not a market at all so much as two of them, with a lower quartile of $215.98 and an upper quartile of $1299[1]. There is no single brand price to compare against.
Why the brand range has two ends
Because two different things are being sold. At the low end, a manufacturer sells directly to cash-paying patients at a published, dose-tiered price. At the high end, a telehealth platform dispenses the same branded product and prices it closer to what a pharmacy counter charges without insurance. Both are the brand. Neither is a compounded drug. The gap between them is distribution.
Across the sellers we review the direct-pay end is represented by LillyDirect and NovoCare Pharmacy, whose lines are priced by dose rather than by plan length. 19 of the 23 brand price lines inside a multi-price group across the sellers we review name a milligram figure in the seller's own label, and 0 name a plan term.
Those milligrams aren't optional. The approved label steps from a 2.5 mg starting dose, which it says is not approved as a maintenance dosage, up to 5, 10 or 15 mg[5]. What that ladder costs as the dose climbs is its own question, and a large one.
A compounded monthly figure that assumes a prepaid year, set beside a brand figure with no term attached. One is a commitment and the other is a price. Every table in this market does it, ours included unless you read the terms column, which is why every price we publish keeps the seller's own wording intact.
The rule that decides whether the cheap tier can exist at all
Federal law lets a compounder prepare a version of a drug that is on the FDA's shortage list, under conditions[2]. That was the door most compounded GLP-1s came through and it has closed. We read the agency's shortage database directly on the day this page was updated[3]: 74 entries, 70 of them currently in shortage. Liraglutide injection is among them. Semaglutide injection and tirzepatide injection are not.
So the price gap now has to justify itself against a different rule — the one about compounded products that are essentially copies of an available drug — rather than against a supply emergency. What compounded actually means, legally walks that whole analysis, and the FDA's guidance on it is explicit that a lower price is not by itself sufficient to establish that a compounded product is not essentially a copy.
What the price difference does not tell you
The trial record on the cheaper product. A PubMed search finds 0 results; the same search for semaglutide finds 306.
The agency's own position is that compounded drugs are not FDA approved and that it does not verify their safety, effectiveness or quality before they are marketed[2]. It also lists a company claiming that a compounded drug is the same as an FDA-approved drug first among its telehealth red flags[4]. A price comparison is not a claim of equivalence, and a seller that turns one into the other has crossed a line the FDA has drawn in writing.
First: does the compounded figure assume a plan term, and does the brand figure? Second: which pharmacy compounds it, and is that a state-licensed pharmacy or a registered outsourcing facility? The second question has nothing to do with price and everything to do with what you are comparing.
Put a real seller's medication price and its recurring fee into the calculator over the months you expect to take it, and the brand-versus-compounded question usually answers itself for your particular case — which is the only case that matters. The full cash range is the wider view.
Questions people actually ask
Is compounded semaglutide always cheaper than Wegovy or Ozempic?
No. Across the sellers we review, 22 of the 91 brand GLP-1 prices we have read sit at or below the middle of the compounded range, and the most expensive compounded line costs more than most brand lines. The ranges overlap in the middle.
Why is brand pricing so different from one seller to another?
Because two different channels are being compared. A manufacturer selling directly to cash-paying patients publishes a dose-tiered price; a telehealth platform dispensing the same branded product prices it closer to a retail pharmacy counter. Both figures are real and they are not comparable.
Is the compounded version the same drug?
It contains the same molecule. It is a different product, made by a different party, under rules that do not include FDA review for safety, effectiveness or quality before marketing. The approved-product trials cited here do not establish equivalence for a compounded preparation.
Is semaglutide still on the FDA shortage list?
Not on the day we read the database. The current and resolved table held 74 entries, 70 marked currently in shortage, and neither semaglutide injection nor tirzepatide injection appeared. Liraglutide injection did, which is what makes the absence of the other two meaningful.
Sources
Primary sources and the claims they support.
- 1.The Telehealth Graded price record. Telehealth Graded, 2026. SourceEvery count, range and quartile comparing the brand and compounded markets in this article is counted from the site's own price records, each read off the seller's own page and stamped with the day we read it.
- 2.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Compounded drugs are not FDA approved and the agency does not verify their safety, effectiveness or quality before marketing; federal law permits compounding a version of a drug on the FDA shortage list under stated conditions; and a lower price is not sufficient to establish that a compounded product is not essentially a copy of an available one.
- 3.FDA Drug Shortages: current and resolved drug shortages. U.S. Food and Drug Administration, accessdata, 2026. SourceThe rendered current-and-resolved index held 74 entries on the day it was read, 70 marked currently in shortage and four resolved. Liraglutide injection appeared as currently in shortage; tirzepatide returned no row at all and semaglutide appeared only as a tablet entry.
- 4.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated September 2026The FDA's telehealth red flags for consumers, the first of which is a company that claims a compounded drug is the same as an FDA-approved drug, and the second of which is a company offering medicine at deep discounts or prices that seem too good to be true.
- 5.ZEPBOUND (tirzepatide) injection — FDA prescribing information. U.S. Food and Drug Administration, Structured Product Labeling, 2026. Source · Document dated August 2026The approved brand product against which a compounded tirzepatide preparation is being priced: a starting dosage of 2.5 mg once weekly, maintenance dosages of 5, 10 or 15 mg, and a maximum of 15 mg once weekly.
Key figures